Century Therapeutics Inc (IPSC)
Century Therapeutics, Inc. is a biotechnology company listed on NASDAQ under the ticker IPSC. The company focuses on developing allogeneic cell therapies for a range of serious diseases, including solid tumors, hematological malignancies, and autoimmune disorders. Its lead candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy designed with Allo-Evasion 5.0 for type 1 diabetes. Century Therapeutics is also advancing CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT therapy with Allo-Evasion 5.0 for B-cell-mediated autoimmune diseases, and CNTY-101, an allogeneic iPSC-derived CAR-iNK therapy with precision gene edits and Allo-Evasion 1.0 intended for CD19-related B-cell autoimmune conditions. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IPSC
|
$2.04
|
8.1% Upside
|
Fair
|
$4.75
|
151.3% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
1.4x
|
342.2 M
|
176.5 M
|
10.2%
|
55.9%
|
-1.8
|
80.2%
|
